The Moat Index
Compare moats, side by side.
Two to four companies, scored on the same five investor questions from their SEC filings — so the comparison is apples to apples. The method is fully public.
OMDA · Healthcare · Narrow moat
On the watchlist
The returnsOnCapital component abstained: Not enough years of ROIC data to score returns on capital. The other four 20% weights were renormalized over the scored 80%.
| Measure | OMDA | STE | IRWD | DRS |
|---|---|---|---|---|
| Moat Score (0–100) | 65 (highest) | 65 (highest) | 65 (highest) | 64 |
| Methodology version | moat-index@2.0.0 | moat-index@2.0.0 | moat-index@2.0.0 | moat-index@2.0.0 |
| Business trend | 70 | 95 (highest) | 72 | 80 |
| Pricing power | 95 | 73 | 99 (highest) | 28 |
| Returns on capital | — | 16 | 91 (highest) | 33 |
| Balance-sheet safety | 55 | 82 | 30 | 100 (highest) |
| Capital discipline | 39 | 60 | 33 | 80 (highest) |
| Price vs. high estimate | No price data | 100% above high estimate (largest discount to high estimate) | 125% above high estimate | 199% above high estimate |
| Market cap | $1.4B | $21.0B | $627.8M | $11.8B |
| Moat tier | Narrow moat | Narrow moat | Narrow moat | Narrow moat |
| Filings as of | FY2025 | FY2026 | FY2025 | FY2025 |